ACR 2022 Tweet by Dr. Antoni Chan
Tweet
Related Content
Drugs commonly used to treat systemic autoimmune rheumatic diseases (SARDs) may keep the SARS-CoV-2 circulating after COVID-19 infection in patients with these conditions, with researchers documenting substantially increased viral antigen persistence compared with other post-COVID patients.
Panelists explore the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy.
Podcast
Replay of RheumNow Live 2025 - Psoriatic Arthritis
Sponsored by AbbVie
Featuring:
Dr. Alexis Ogdie - Can Aggressive Treatment of Psoriasis Prevent PsA?
Dr. Artie Kavanaugh - Combination Biologic Therapies in PsA
Dr. Kenneth Gordon - Head-to-head Studies in Psoriatic Disease – What have we learned?
